

# Francois Meyer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12052124/publications.pdf>

Version: 2024-02-01

41  
papers

3,034  
citations

172386

29  
h-index

265120

42  
g-index

42  
all docs

42  
docs citations

42  
times ranked

3647  
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2019, 48, 4.	0.9	24
2	Predictors of circulating INTERLEUKIN-6 levels in head and neck cancer patients. <i>Cancers of the Head &amp; Neck</i> , 2018, 3, .	6.2	7
3	A genome-wide association study of non-HPV-related head and neck squamous cell carcinoma identifies prognostic genetic sequence variants in the MAP-kinase and hormone pathways. <i>Cancer Epidemiology</i> , 2016, 42, 173-180.	0.8	4
4	Genetic sequence variants in vitamin D metabolism pathway genes, serum vitamin D level and outcome in head and neck cancer patients. <i>International Journal of Cancer</i> , 2013, 132, 2520-2527.	2.3	16
5	Predictors of Severe Acute and Late Toxicities in Patients With Localized Head-and-Neck Cancer Treated With Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1454-1462.	0.4	81
6	Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival. <i>Clinical Cancer Research</i> , 2012, 18, 196-206.	3.2	39
7	Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers. <i>Cancer</i> , 2012, 118, 1554-1565.	2.0	15
8	Factors associated with weight loss during radiotherapy in patients with stage I or II head and neck cancer. <i>Supportive Care in Cancer</i> , 2012, 20, 591-599.	1.0	39
9	Dietary vitamin D intake and serum 25-hydroxyvitamin D level in relation to disease outcomes in head and neck cancer patients. <i>International Journal of Cancer</i> , 2011, 128, 1741-1746.	2.3	28
10	Predictors of weight loss during radiotherapy in patients with stage I or II head and neck cancer. <i>Cancer</i> , 2010, 116, 2275-2283.	2.0	57
11	Serum Prognostic Markers in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 1008-1015.	3.2	39
12	Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis. <i>Human Pathology</i> , 2010, 41, 1694-1701.	1.1	21
13	Health-Related Quality of Life As a Survival Predictor for Patients With Localized Head and Neck Cancer Treated With Radiation Therapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 2970-2976.	0.8	83
14	Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: A randomized trial among head and neck cancer patients. <i>International Journal of Cancer</i> , 2008, 122, 1679-1683.	2.3	106
15	Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. <i>Human Pathology</i> , 2008, 39, 731-739.	1.1	49
16	Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 490-499.	1.1	55
17	Prognostic Significance of Cyclooxygenase-2 Overexpression in Glottic Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 67-73.	3.2	25
18	Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies. <i>Annals of Internal Medicine</i> , 2008, 149, 461.	2.0	263

#	ARTICLE	IF	CITATIONS
19	Acute Adverse Effects of Radiation Therapy and Local Recurrence in Relation to Dietary and Plasma Beta Carotene and Alpha Tocopherol in Head and Neck Cancer Patients. <i>Nutrition and Cancer</i> , 2007, 59, 29-35.	0.9	24
20	Antioxidant vitamins supplementation and mortality: A randomized trial in head and neck cancer patients. <i>International Journal of Cancer</i> , 2006, 119, 2221-2224.	2.3	149
21	Insulin-Like Growth Factor Binding Protein 2: An Androgen-Dependent Predictor of Prostate Cancer Survival. <i>European Urology</i> , 2005, 47, 695-702.	0.9	26
22	Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. <i>International Journal of Cancer</i> , 2005, 116, 182-186.	2.3	212
23	A Prospective Study of the Insulin-Like Growth Factor Axis in Relation with Prostate Cancer in the SU.VI.MAX Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2269-2272.	1.1	18
24	A Randomized Trial of Antioxidant Vitamins to Prevent Second Primary Cancers in Head and Neck Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2005, 97, 481-488.	3.0	209
25	Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 5805-5813.	0.8	242
26	Antihypertensive Drug Use and The Risk of Prostate Cancer (Canada). <i>Cancer Causes and Control</i> , 2004, 15, 535-541.	0.8	140
27	Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. <i>International Journal of Cancer</i> , 2003, 106, 409-415.	2.3	69
28	Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. <i>Cancer Research</i> , 2003, 63, 8511-5.	0.4	88
29	Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. <i>International Journal of Cancer</i> , 2001, 95, 135-139.	2.3	33
30	Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes. <i>International Journal of Cancer</i> , 2000, 89, 100-104.	2.3	31
31	Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. <i>Oncogene</i> , 2000, 19, 6317-6323.	2.6	62
32	Lifetime occupational physical activity and incidental prostate cancer (Canada). <i>Cancer Causes and Control</i> , 2000, 11, 759-764.	0.8	41
33	Dietary fat and prostate cancer survival. <i>Cancer Causes and Control</i> , 1999, 10, 245-251.	0.8	93
34	DOWNWARD TREND IN PROSTATE CANCER MORTALITY IN QUEBEC AND CANADA. <i>Journal of Urology</i> , 1999, 161, 1189-1191.	0.2	50
35	NEOADJUVANT HORMONAL THERAPY BEFORE RADICAL PROSTATECTOMY AND RISK OF PROSTATE SPECIFIC ANTIGEN FAILURE. <i>Journal of Urology</i> , 1999, 162, 2024-2028.	0.2	58
36	Deletions of the INK4A Gene in Superficial Bladder Tumors. <i>American Journal of Pathology</i> , 1999, 155, 105-113.	1.9	121

#	ARTICLE	IF	CITATIONS
37	DIETARY FAT AND ADVANCED PROSTATE CANCER. <i>Journal of Urology</i> , 1998, 159, 1271-1275.	0.2	75
38	Dietary energy and nutrients in relation to preclinical prostate cancer. <i>Nutrition and Cancer</i> , 1997, 29, 120-126.	0.9	67
39	High levels of PCBs in breast milk of inuit women from arctic quebec. <i>Bulletin of Environmental Contamination and Toxicology</i> , 1989, 43, 641-646.	1.3	187
40	Dietary Fat in Relation to Prognostic Indicators in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 1988, 80, 819-825.	3.0	59
41	Maternal and neonatal morbidity in instrumental deliveries with the kobayashi vacuum extractor and low forceps. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 1987, 66, 643-647.	1.3	26